Brief: Quantum Genomics Announces Positive FDA Feedback

Quantum Genomics SA

02/09/2019 17:10

Sept 2 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * QUANTUM GENOMICS ANNOUNCES POSITIVE FDA FEEDBACK ON PHASE
III
PROGRAM DESIGN OF FIRIBASTAT IN RESISTANT ARTERIAL HYPERTENSION
    * RECEIVED FAVOURABLE FEEDBACK FDA ON COMPANY'S PHASE III
DEVELOPMENT PLAN AND TRIAL DESIGN FOR FIRIBASTAT
    * EFFICACY STUDY, QGC001/3QG1, WILL BE A THREE-MONTH
DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY
    * PIVOTAL PHASE III EFFICACY STUDY OF FIRIBASTAT IN
DIFFICULT-TO-T
PIVOTAL PHASE III EFFICACY STUDY WILL THUS START BY END OF 2019
    * PIVOTAL PHASE III EFFICACY STUDY OF FIRIBASTAT IN
DIFFICULT-TO-TREAT OR TREATMENT-RESISTANT ARTERIAL HYPERTENSION
RESULTS WILL BE AVAILABLE IN H2 2021
    * PIVOTAL PHASE III EFFICACY STUDY OF FIRIBASTAT WILL THUS
START
BY END OF 2019 

Source text for Eikon:  ID:nGNXbYS2PT 
Further company coverage:  ALQGC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))